tbuckley/cabot-search huggingface dataset:
P3.01-48 The Efficiency of Low-Dose Apatinib in Treatment of Advanced Lung Squamous Cell Carcinoma
Authors: Y. Jia, T. Li, S. Wang, K. Lei, B. Tan, L. Qiu, M. Jiang, J. Jiang, L. Du, Y. Qiu, X. Zhang, M. Hu, W. Ye, Y. Jiang
Journal: Journal of Thoracic Oncology (2018)
Intravenous Iron in Patients Undergoing Maintenance Hemodialysis
Authors: Iain C. Macdougall, Claire White, Stefan D. Anker, Sunil Bhandari, Kenneth Farrington, Philip A. Kalra, John J.V. McMurray, Heather Murray, Charles R.V. Tomson, David C. Wheeler, Christopher G. Winearls, Ian Ford
Journal: New England Journal of Medicine (2018)

Intravenous iron is a standard treatment for patients undergoing hemodialysis, but comparative data regarding clinically effective regimens are limited.In a multicenter, open-label trial with blinded end-point evaluation, we randomly assigned adults undergoing maintenance hemodialysis to receive either high-dose iron sucrose, administered intravenously in a proactive fashion (400 mg monthly, unless the ferritin concentration was >700 μg per liter or the transferrin saturation was ≥40%), or low-dose iron sucrose, administered intravenously in a reactive fashion (0 to 400 mg monthly, with a ferritin concentration of <200 μg per liter or a transferrin saturation of <20% being a trigger for iron administration). The primary end point was the composite of nonfatal myocardial infarction, nonfatal stroke, hospitalization for heart failure, or death, assessed in a time-to-first-event analysis. These end points were also analyzed as recurrent events. Other secondary end points included death, infection rate, and dose of an erythropoiesis-stimulating agent. Noninferiority of the high-dose group to the low-dose group would be established if the upper boundary of the 95% confidence interval for the hazard ratio for the primary end point did not cross 1.25.A total of 2141 patients underwent randomization (1093 patients to the high-dose group and 1048 to the low-dose group). The median follow-up was 2.1 years. Patients in the high-dose group received a median monthly iron dose of 264 mg (interquartile range [25th to 75th percentile], 200 to 336), as compared with 145 mg (interquartile range, 100 to 190) in the low-dose group. The median monthly dose of an erythropoiesis-stimulating agent was 29,757 IU in the high-dose group and 38,805 IU in the low-dose group (median difference, -7539 IU; 95% confidence interval [CI], -9485 to -5582). A total of 320 patients (29.3%) in the high-dose group had a primary end-point event, as compared with 338 (32.3%) in the low-dose group (hazard ratio, 0.85; 95% CI, 0.73 to 1.00; P<0.001 for noninferiority; P=0.04 for superiority). In an analysis that used a recurrent-events approach, there were 429 events in the high-dose group and 507 in the low-dose group (rate ratio, 0.77; 95% CI, 0.66 to 0.92). The infection rate was the same in the two groups.Among patients undergoing hemodialysis, a high-dose intravenous iron regimen administered proactively was superior to a low-dose regimen administered reactively and resulted in lower doses of erythropoiesis-stimulating agent being administered. (Funded by Kidney Research UK; PIVOTAL EudraCT number, 2013-002267-25 .).
P2.03-02 Cell-Free DNA (cfDNA) Testing in Lung Adenocarcinoma (LUAC) Patients: Spanish Lung Liquid Versus Invasive Biopsy Program (SLLIP)
Authors: R. Palmero, A. Taus, S. Viteri, M. Majem, E. Carcereny, J. Garde-Noguera, E. Felip, M. Sampayo, L. Gomez, N. Lopez, S. Olsen, M. Jackson, I. Faull, D. Dix, N. Karachaliou, R. Rosell
Journal: Journal of Thoracic Oncology (2018)
Alienor/ENGOT-ov7 randomized trial exploring weekly paclitaxel (wP) + bevacizumab (bev) vs wP alone for patients with ovarian sex cord tumors (SCT) in relapse
Authors: I.L. Ray-Coquard, P. Harter, D. Lorusso, C. Dalban, I.B. Vergote, K. Fujiwara, L. Gladieff, H.-J. Lueck, A. Floquet, A.F. Lesoin, A. Schnelzer, S. Pignata, F. Selle, J. Sehouli, F. Brocard, G. Mangili, P. Pautier, U. De Giorgi, M. Provansal, P.-E. Heudel
Journal: Annals of Oncology (2018)
P2.16-04 Prognostic Value of Lymphovascular Invasion and Its Effect on Patterns of Recurrence in T1-3N0 Non-Small Cell Lung Cancer
Authors: Y.S. Kim, J.H. Hong, S.Y. Sung, Y. Kwak, S. Lee, J.K. Park, K.S. Kim, K.Y. Lee
Journal: Journal of Thoracic Oncology (2018)
OMTX705, a powerful stroma-targeting ADC to treat invasive tumors with low response to immunotherapeutic anti-PD-1 treatments
Authors: M. Fabre, C. Ferrer, S. Dominguez-Hormaetxe, R. Kontermann, K. Pfizenmaier, O. Seifert, P.P. López-Casas, M. Abbas, W. Richter, L. Simon, M. Hidalgo
Journal: Annals of Oncology (2018)
P1.12-01 A Single-Arm Multi-Center Phase II Study of Apatinib in Patients with ES-SCLC After Second/Third-Line Chemotherapy
Authors: Y. Fan, Z. Huang, W. Li, Y. Li, J. Chen, Y. Xu, H. Lu, X. Yu, Y. Xu, J. Qin, Y. Jin, X. Xu, L. Gong, F. Xie, N. Han, P. Zhang, K. Chen
Journal: Journal of Thoracic Oncology (2018)
Initial results from a phase IIIb/IV study evaluating two dosing regimens of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 511)
Authors: C. Lebbé, N. Meyer, L. Mortier, I. Marquez-Rodas, C. Robert, P. Rutkowski, A.M. Menzies, T. Eigentler, P.A. Ascierto, M. Smylie, M. Ajaz, I.-M. Svane, R. Gonzalez, L. Rollin, A. Saci, E. Grigoryeva, J. Pigozzo
Journal: Annals of Oncology (2018)
AZD8186, a potent and selective inhibitor of PI3Kβ/δ, as monotherapy and in combination with abiraterone acetate plus prednisone (AAP), in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)
Authors: J.S. de Bono, A. Hansen, A.D. Choudhury, N. Cook, E.I. Heath, C. Higano, M. Linch, J. Martin-Liberal, D.E. Rathkopf, K.B. Wisinski, S. Barry, E. de Bruin, W. Brugger, S. Colebrook, T. Klinowska, M. Moschetta, P.G.S. Mortimer, L.L. Siu, G. Shapiro
Journal: Annals of Oncology (2018)
OA02.03 Clinical Activity of Lorlatinib in Patients with ROS1+ Advanced Non-Small Cell Lung Cancer: Phase 2 Study Cohort EXP-6
Authors: S. Ou, A. Shaw, G. Riely, R. Chiari, J. Bauman, J. Clancy, H. Thurm, G. Peltz, A. Abbattista, B. Solomon
Journal: Journal of Thoracic Oncology (2018)
P3.16-05 A Nanotechnology-Enabled Strategy for Image-Guided Transbronchial and Transpleural Photothermal Therapy of Peripheral Lung Cancer
Authors: T. Kinoshita, H. Ujiie, J. Chen, L. Ding, H. Chan, A. Gregor, N. Bernards, P. Mcveigh, K. Fujino, C. Lee, Y. Motooka, T. Inage, M. Valic, R. Weersink, B. Wilson, G. Zheng, H. Asamura, K. Yasufuku
Journal: Journal of Thoracic Oncology (2018)
P1.04-20 Computational Biological Model Prediction of PD-L1 Expression and Immunotherapy Response for KRAS Mutated Lung Cancer Based on Co-Mutations
Authors: S. Padda, J. Aredo, S. Vali, N. Singh, S. Vasista, U. Mitra, T. Abbasi, H. Wakelee
Journal: Journal of Thoracic Oncology (2018)
P2.01-21 Antigen Cascade Triggering Correlates with Prolonged Survival in Advanced NSCLC Patients Undergone PD-1 Blockade with Nivolumab.
Authors: P. Correale, R. Giannicola, G. D'Arrigo, P. Pastina, V. Nardone, C. Botta, V. Barbieri, G. Tripepi, M. Monoriti, L. Pirtoli, R. Saladino, A. Falzea, P. Tagliaferri
Journal: Journal of Thoracic Oncology (2018)
P2.01-34 Prognostic Value of Neutrophil to Lymphocyte Ratio for Metastatic NSCLC Patients Treated with Immunotherapy and Ramucirumab Plus Docetaxel.
Authors: I. Fughhi, P. Bonomi, M.J. Fidler, S. Basu, J. Borgia, M. Batus
Journal: Journal of Thoracic Oncology (2018)
miR-31 as a prognostic and predictive marker of disease-free survival (DFS) in resected stage III colon cancer: A retrospective analysis of the PETACC-8 trial
Authors: Y. Gaston Mathe, S. Martin-Lannerée, C. Vazart, K. Fontaine, C. Mulot, A. Caumont, F. Montestruc, K. Le Malicot, C. Lepage, J. Taieb, P. Laurent-Puig
Journal: Annals of Oncology (2018)
MA02.06 A Randomized, Double-Blind, Placebo-Controlled Trial of Chemotherapy Combined with Yangzheng Xiaoji in Advanced NSCLC
Authors: L. Xing, J. Wang, L. Li, Z. Ma, C. Hu, H. Zhang, L. Shan, Z. Chen, J. Zhang, Q. Zhou, S. Gao, X. Ma, P. Sun, Q. Ren, M. Wu, J. Wu, J. Li, J. Yao, H. Ma, W. Wang, W. Yao, D. Wang, J. Kang, G. Li, X. Wang, W. Zhu, J. Wang, J. Yu
Journal: Journal of Thoracic Oncology (2018)
P2.16-20 Prognostic Utility of PET in Non-Small Cell Lung Cancer After Empiric Stereotactic Body Radiotherapy (SBRT)
Authors: S. Hasan, R. Petek, D. Petrov, A. Colonias, T. Mickus, M. Van Deusen, R. Wegner
Journal: Journal of Thoracic Oncology (2018)
P1.04-31 Efficacy and Tolerance of Immune-Checkpoint Inhibitors in EGFR, ALK/ROS 1 Non-Small-Cell-Lung-Cancer (NSCLC): GFPC 03-2016 IMAD Study
Authors: O. Bylicki, F. Guisier, I. Monnet, H. Doubre, R. Gervais, H. Janicot, M. Pérol, P. Fournel, J. Le Treut, R. Lamy, S. Vieillot, H. Le Caer, J. Auliac, C. Chouaid
Journal: Journal of Thoracic Oncology (2018)
Efficacy and safety of radiofrequency ablation of Barrett’s esophagus in the absence of reimbursement: a multicenter prospective Belgian registry
Authors: Joke Vliebergh, Pierre Deprez, Danny de Looze, Marc Ferrante, Hans Orlent, Elisabeth Macken, Paul Christiaens, Fazia Mana, Gert De Hertogh, Hilde Willekens, Raf Bisschops
Journal: Endoscopy (2018)

Abstract Background Radiofrequency ablation (RFA), combined with endoscopic resection, can be used as a primary treatment for low grade dysplasia, high grade dysplasia, and early esophageal adenocarcinoma (EAC) in Barrett’s esophagus (BE). The aim of the Belgian RFA registry is to capture the real-life outcome of endoscopic therapy for BE with RFA and to assess efficacy and safety outside study protocols, in the absence of reimbursement. Patients and methods Between February 2008 and January 2017, data from 7 different expert centers were prospectively collected in the registry. Efficacy outcomes included complete remission of intestinal metaplasia (CR-IM), complete remission of dysplasia (CR-D), and durability of remission. Safety outcomes included immediate and late adverse events. Results 684 RFA procedures in 342 different patients were registered. Of these, 295 patients were included in the efficacy analysis, with CR-IM achieved in 88 % and CR-D in 93 %, in per-protocol analysis; corresponding rates in intention-to-treat analysis were 82 % and 87 %, respectively. Sustained remission was seen in 65 % with a median (interquartile range) follow-up of 25 (12 – 47) months. No risk factors for recurrent disease were identified. Immediate complications occurred in 4 % of all procedures and 6 % of all patients, whereas late complications occurred in 9 % of all procedures and in 20 % of all patients. Conclusions Data from the Belgian registry confirm that RFA in combination with endoscopic resection is an efficient treatment for BE with dysplasia or early EAC. In the absence of reimbursement, more rescue treatments are used, not compromising outcome. Since there is recurrent disease after CR-IM in 35 %, surveillance endoscopy remains necessary.
P1.11-18 A Classification-Based Machine Learning Method Reveals Exosomal miRNA Biomarkers for Patients with Pulmonary Ground Glass Nodule
Authors: J. Zhang, J. Xu, J. Su, R. Fu, J. Lin, B. Jiang, S. Dong, R. Liao, X. Yang, H. Qin, F. Li, L. Xiong, Y. Wu, W. Zhong
Journal: Journal of Thoracic Oncology (2018)
Breast cancer (BC) related fatigue: A longitudinal investigation of its prevalence, domains and correlates
Authors: I. Vaz Luis, A. Di Meglio, M. El-Mouhebb, A. Dumas, C. Charles, G. Menvielle, C. Mesleard, A.L. Martin, P.H. Cottu, F. Lerebours, C. Coutant, A. Lesur, S. Dauchy, P. Arveux, S. Delaloge, N. Lin, P. Ganz, A.H. Partridge, S. Michiels, F. André
Journal: Annals of Oncology (2018)
Updated efficacy and safety data of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E–mutated anaplastic thyroid cancer (ATC)
Authors: B. Keam, R.J. Kreitman, Z.A. Wainberg, M.E. Cabanillas, D.C. Cho, A. Italiano, A. Stein, J.Y. Cho, J.H.M. Schellens, P.Y. Wen, C.C. Zielinski, A.D. Boran, B. Mookerjee, P. Burgess, F. Rangwala, V. Subbiah
Journal: Annals of Oncology (2018)
Bullying and harassment cost NHS over £2bn a year, study suggests
Authors: Ingrid Torjesen
Journal: BMJ (2018)

The consequences of bullying and harassment in the NHS cost the service in England at least £2.28bn (€2.58bn; $2.96bn) a year, an analysis suggests.1

Researchers used data from NHS Digital to gauge the impact of bullying and harassment on sickness absence, employee turnover, productivity, sickness presenteeism, and employment relations. The authors described the final £2.28bn figure as an “extremely cautious” estimate, as several costs lack reliable evidence.

The analysis, published in the journal Public Money and Management ,1 estimated that the cost to the …
Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC), including the nivolumab 1 mg/kg + ipilimumab 3 mg/kg expansion from CheckMate 032
Authors: J.E. Rosenberg, P. Sharma, F.G.M. de Braud, U. Basso, E. Calvo, P. Bono, M. Morse, P.A. Ascierto, J.A. Lopez-Martin, P. Brossart, K.S. Rohrberg, N. Reguart, W.H. Lin, S. Meadows-Shropshire, A. Saci, M. Callahan, A.O. Siefker-Radtke
Journal: Annals of Oncology (2018)
OA09.07 Association Between Outdoor Air Pollution And Lung Cancer in Female Never Smokers
Authors: R. Myers, M. Brauer, S. Ladhar, S. Atkar-Khattra, J. Yee, C. Ho, A. Mcguire, K. Grant, A. Lee, B. Melosky, S. Sun, M. Tammemägi, S. Lam
Journal: Journal of Thoracic Oncology (2018)
Preoperative c-reactive protein and thrombocyte count as potential markers for longterm survival in ovarian cancer
Authors: E.I. Braicu, J. Sehouli, R. Richter, I.B. Vergote, N. Concin, E. van Nieuwenhuysen, P. Achimas, A. Berger, B. Fetica, S. Mahner, J. Glajzer, A. Papadia, L. Woelber, M.L. Gasparri, A. Vanderstichele, P. Benedetti Panici, M. Mueller, I. Ruscito, J. Zimmer, H. Woopen
Journal: Annals of Oncology (2018)
Gastroesophageal Reflux After Sleeve Gastrectomy
Authors: Marco G. Patti, Francisco Schlottmann
Journal: JAMA Surgery (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Prognostic factors of chemo-radiotherapy efficacy in patients with locally-advanced rectal cancer
Authors: M. Fedyanin, A. Tryakin, I. Pokataev, A. Bulanov, O. Sekhina, D. Chekini, S. Gordeev, V. Aliev, D. Kuzmichev, Z. Mamedli, Y. Barsukov, V. Glebovskaya, S. Tkachev, M. Chernykh, N. Kozlov, S. Tjulandin
Journal: Annals of Oncology (2018)
PL02.07 IMpower 133: Primary PFS, OS and Safety in a PH1/3 Study of 1L Atezolizumab + Carboplatin + Etoposide in Extensive-Stage SCLC
Authors: S. Liu, A. Mansfield, A. Szczesna, L. Havel, M. Krzakowski, M. Hochmair, F. Huemer, G. Losonczy, M. Johnson, M. Nishio, M. Reck, T. Mok, S. Lam, D. Shames, J. Liu, B. Ding, F. Kabbinavar, W. Lin, A. Sandler, L. Horn
Journal: Journal of Thoracic Oncology (2018)
Efficacy and safety of vandetanib for patients with advanced and progressive medullary thyroid cancer (MTC) as systemic treatment beyond first-line therapy
Authors: J. Hernando Cubero, E. Grande, P. Jimenez Fonseca, C. Villabona, J.M. Trigo Perez, J. Martinez Trufero, I. Pajares Bernad, C. Lopez, T. Alonso, J. Biarnes, T. RamónY Cajal, M. Duran, J.J. Grau, S. Arevalo Lobera, R. Mesia Nin, M. Llanos, E. Dalmau Portulas, C. Alvarez, C. Zafon, J. Capdevila
Journal: Annals of Oncology (2018)
P2.03-09 The Real World of NTRK Fusion Data in the Chinese Lung Cancer Populations: A Multicenter Study
Authors: W. Wang, C. Xu, Y. Zhu, Y. Liu, Y. Chen, Q. Zhang, H. Wang, W. Zhuang, X. Chen, J. Lai, M. Fang, Y. Tao, S. Xu, X. Qian, H. Zhao, S. Cai, G. Chen, T. Lv, Y. Song
Journal: Journal of Thoracic Oncology (2018)
Thermal liquid biopsy as a new tool for lung cancer patients diagnostic: Pilot study
Authors: A. Rodrigo, O. Abian, A. Velazquez-Campoy, A. Callejo, S. Vega, A. Fernandez, O. Sánchez-Gracia, P. Iranzo Gomez, M. Cruellas, E. Quilez Bielsa, D. Isla
Journal: Annals of Oncology (2018)
Safety run-in evaluation of the phase I trial of trifluridine/tipiracil (FTD/TPI) in combination with oxaliplatin and a monoclonal antibody (bevacizumab or nivolumab) in patients (pts) with metastatic colorectal cancer (mCRC)
Authors: A. Calvo Ferrandiz, L. Dahan, A. Hollebecque, G. Prager, T. Andre, G. Argiles Martinez, R. Bordonaro, A. Stein, G. Tortora, C. Leger, N. Amellal, J. Tabernero
Journal: Annals of Oncology (2018)
P1.04-14 HLA B44 Supertype Associated with Less Favorable Neoantigen Binding in Non-Small Cell Lung Cancer Treated with Immunotherapy
Authors: A. Cummings, H. Lu, J. Gukasyan, J. Madrigal, J. Carroll, K. Bornazyan, B. Jones, Z. Noor, A. Lisberg, J.W. Goldman, S. Hu-Lieskovan, S. Dubinett, E. Garon
Journal: Journal of Thoracic Oncology (2018)
Diagnosis of Pulmonary Embolism During Pregnancy
Authors: Marc Righini, Helia Robert-Ebadi, Antoine Elias, Olivier Sanchez, Emmanuelle Le Moigne, Jeannot Schmidt, Catherine Le Gall, Jacques Cornuz, Drahomir Aujesky, Pierre-Marie Roy, Céline Chauleur, Olivier T. Rutschmann, Pierre-Alexandre Poletti, Grégoire Le Gal
Journal: Annals of Internal Medicine (2018)

Background: Data on the optimal diagnostic management of pregnant women with suspected pulmonary embolism (PE) are limited, and guidelines provide inconsistent recommendations on use of diagnostic tests. Objective: To prospectively validate a diagnostic strategy in pregnant women with suspected PE. Design: Multicenter, multinational, prospective diagnostic management outcome study involving pretest clinical probability assessment, high-sensitivity D-dimer testing, bilateral lower limb compression ultrasonography (CUS), and computed tomography pulmonary angiography (CTPA). (ClinicalTrials.gov: NCT00740454) Setting: 11 centers in France and Switzerland between August 2008 and July 2016. Patients: Pregnant women with clinically suspected PE in emergency departments. Intervention: Pulmonary embolism was excluded in patients with a low or intermediate pretest clinical probability and a negative D-dimer result. All others underwent lower limb CUS and, if results were negative, CTPA. A ventilation–perfusion (V/Q) scan was done if CTPA results were inconclusive. Pulmonary embolism was excluded if results of the diagnostic work-up were negative, and untreated pregnant women had clinical follow-up at 3 months. Measurements: The primary outcome was the rate of adjudicated venous thromboembolic events during the 3-month follow-up. Results: 441 women were assessed for eligibility, and 395 were included in the study. Among these, PE was diagnosed in 28 (7.1%) (proximal deep venous thrombosis found on ultrasonography [n = 7], positive CTPA result [n = 19], and high-probability V/Q scan [n = 2]) and excluded in 367 (clinical probability and negative D-dimer result [n = 46], negative CTPA result [n = 290], normal or low-probability V/Q scan [n = 17], and other reason [n = 14]). Twenty-two women received extended anticoagulation during follow-up, mainly for previous venous thromboembolic disease. The rate of symptomatic venous thromboembolic events was 0.0% (95% CI, 0.0% to 1.0%) among untreated women after exclusion of PE on the basis of negative results on the diagnostic work-up. Limitation: There were several protocol deviations, reflecting the difficulty of performing studies in pregnant women with suspected PE. Conclusion: A diagnostic strategy based on assessment of clinical probability, D-dimer measurement, CUS, and CTPA can safely rule out PE in pregnant women. Primary Funding Source: Swiss National Foundation for Scientific Research, Groupe d'Etude de la Thrombose de Bretagne Occidentale, and International Society on Thrombosis and Haemostasis.
Efficacy and safety of nab-paclitaxel plus gemcitabine (AG) vs. FOLFIRINOX (FFX) as first line chemotherapy for metastatic pancreatic cancer (mPC): Retrospective analysis
Authors: K. Lee, I. Hwang, J. Kang, C. Yoo, K.-P. Kim, J.H. Jeong, H.-M. Chang, B.-Y. Ryoo
Journal: Annals of Oncology (2018)
OA01.03 Interaction Between Dose and Calcifications Is a Predictor for Overall Survival in Lung Cancer Patients Receiving Radiotherapy
Authors: E. Vasquez Osorio, F. Brewster, D. Cobben, C. Faivre-Finn, A. Scaife, M. Van Herk, A. McWilliam
Journal: Journal of Thoracic Oncology (2018)
Novel small-molecule RORγ agonist immuno-oncology agent LYC-55716: Safety and efficacy in a phase IIA open-label, multicenter trial
Authors: J. Wang, S.V. Liu, H.E. Uronis, C. Wu, D. Mahalingam, A. Spira, L. Carter, X. Hu, G. Weems, H.J. Wilkins, L.R. Duska, K. Kelly
Journal: Annals of Oncology (2018)
Treatment patterns and changes in quality of life during first-line palliative chemotherapy in Korean patients with advanced gastric cancer
Authors: K.-W. Lee, J.W. Kim, J.G. Kim, B.W. Kang, I.J. Chung, Y.S. Hong, T.-Y. Kim, K.H. Lee, D.Y. Zang, Y.H. Ko, E.-K. Song, J.H. Baek, D. Koo, S.Y. Oh, H. Cho
Journal: Annals of Oncology (2018)
Association of efficacy and immune-related adverse events (irAEs) in patients with NSCLC receiving immune-checkpoint inhibitors (ICIs)
Authors: M. Riudavets Melia, I. Gabriela Sullivan, A. Barba Joaquín, G. Anguera Palacios, L.P. del Carpio, C. Molto Valiente, S.D. Camacho Arellano, S. Moron Asensio, P. Gomila Pons, M. Andres Granyó, D. Castillo Villegas, C. Facundo Molas, E. Garcia Planella, C. González Blanco, A. Barnadas Molins, I. Gich Saladich, M. Majem Tarruella
Journal: Annals of Oncology (2018)
Monolithic and Scalable Au Nanorod Substrates Improve PEDOT–Metal Adhesion and Stability in Neural Electrodes
Authors: Mehran Ganji, Lorraine Hossain, Atsunori Tanaka, Martin Thunemann, Eric Halgren, Vikash Gilja, Anna Devor, Shadi A. Dayeh
Journal: Advanced Healthcare Materials (2018)

Poly(3,4-ethylenenedioxythiophene) or PEDOT is a promising candidate for next-generation neuronal electrode materials but its weak adhesion to underlying metallic conductors impedes its potential. An effective method of mechanically anchoring the PEDOT within an Au nanorod (Au-nr) structure is reported and it is demonstrated that it provides enhanced adhesion and overall PEDOT layer stability. Cyclic voltammetry (CV) stress is used to investigate adhesion and stability of spin-cast and electrodeposited PEDOT. The Au-nr adhesion layer permits 10 000 CV cycles of coated PEDOT film in phosphate buffered saline solution without delamination nor significant change of the electrochemical impedance, whereas PEDOT coating film on planar Au electrodes delaminates at or below 1000 cycles. Under CV stress, spin-cast PEDOT on planar Au delaminates, whereas electroplated PEDOT on planar Au encounters surface leaching/decomposition. After 5 weeks of accelerated aging tests at 60 °C, the electrodeposited PEDOT/Au-nr microelectrodes demonstrate a 92% channel survival compared to only 25% survival for spin-cast PEDOT on planar films. Furthermore, after a 10 week chronic implantation onto mouse barrel cortex, PEDOT/Au-nr microelectrodes do not exhibit delamination nor morphological changes, whereas the conventional PEDOT microelectrodes either partially or fully delaminate. Immunohistochemical evaluation demonstrates no or minimal response to the PEDOT implant.